DTIL
HealthcarePrecision BioSciences, Inc.
$4.08
$-0.02 (-0.49%)
Jan 5, 2026
Price History (1Y)
Analysis
Precision BioSciences, Inc. is a biotechnology company that operates in the healthcare sector. The company has a market capitalization of $98.21M and employs 67 individuals. As a biotech firm, it falls within the industry's typical scale. Financially, Precision BioSciences has reported significant losses, with net income totaling -$83,602,000 over the trailing twelve months. The company's margins are largely negative, with an operating margin of -158976.9% and a profit margin of 0.0%. Return on equity is -205.2%, while return on assets is -45.3%. The balance sheet shows $44.87M in cash and $29.13M in debt, resulting in a debt to equity ratio of 175.11. The company's valuation metrics include a price to book ratio of 2.96, a price to sales ratio of 140.71, and an EV/EBITDA of -0.44. The forward P/E ratio is -1.31, indicating significant variation from the trailing twelve months' P/E ratio, which is not available. Revenue growth has been substantial, decreasing by -97.7% year-over-year.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Visit website →Key Statistics
- Market Cap
- $98.21M
- P/E Ratio
- N/A
- 52-Week High
- $8.82
- 52-Week Low
- $3.89
- Avg Volume
- 222.38K
- Beta
- 1.20
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 67